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Abstract
Introduction: Overexpression on plasma membrane of human epidermal growth factor receptor 2 (HER2) is reported 
in 25% to 30% of breast cancers. Heterodimer formation with cognate members of the epidermal growth factor 
receptor (EGFR) family, such as HER3 and EGFR, activates abnormal cell-signalling cascades responsible for 
tumorigenesis and further transcriptional HER2 gene upregulation. Targeting the molecular mechanisms controlling 
HER2 overexpression and recycling may effectively deactivate this feedback-amplification loop. We recently showed 
that inactivation of phosphatidylcholine-specific phospholipase C (PC-PLC) may exert a pivotal role in selectively 
modulating the expression on the membrane of specific receptors or proteins relevant to cell function. In the present 
study, we investigated the capability of PC-PLC inhibition to target the molecular mechanisms controlling HER2 
overexpression on the membrane of breast cancer cells by altering the rates of its endocytosis and lysosomal 
degradation.
Methods: Localization on the membrane and interaction of PC-PLC with HER2, EGFR, and HER3 were investigated on 
HER2-overexpressing and HER2-low breast cancer cell lines, by using confocal laser scanning microscopy, flow 
cytometry, cell-surface biotinylation, isolation of lipid rafts, and immunoprecipitation experiments. The effects of the 
PC-PLC inhibitor tricyclodecan-9-yl-potassium xanthate (D609) on HER2 expression on the membrane and on the 
levels of overall HER2, HER2-HER3, and HER2-EGFR contents were monitored in the HER2-overexpressing SKBr3 cells, 
after either transient or continuous receptor engagement with anti-HER2 monoclonal antibodies, including 
trastuzumab. Changes of HER2 expression and cell proliferation were examined in SKBr3, BT-474, and MDA-MB-453 
cells continuously exposed to D609 alone or combined with trastuzumab.
Results: PC-PLC selectively accumulates on the plasma membrane of HER2-overexpressing cells, where it colocalizes 
and associates with HER2 in raft domains. PC-PLC inhibition resulted in enhanced HER2 internalization and lysosomal 
degradation, inducing downmodulation of HER2 expression on the membrane. Moreover, PC-PLC inhibition resulted in 
strong retardation of HER2 reexpression on the membrane and a decrease in the overall cellular contents of HER2, 
HER2-HER3, and HER2-EGFR heterodimers. The PC-PLC inhibitor also induced antiproliferative effects, especially in 
trastuzumab-resistant cells.
Conclusions: The results pointed to PC-PLC inhibition as a potential means to counteract the tumorigenic effects of 
HER2 amplification and complement the effectiveness of current HER2-targeting therapies.
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Introduction
Mutation and dysregulation of epidermal growth factor
receptor (EGFR) family members are related to cancer
onset and progression [1,2]. In particular, overexpression
of the protooncogene encoding for human epidermal
growth factor receptor 2 (HER2 or ErbB2 or C-neu) is
implicated in a variety of tumors [3,4], with an estimated
p r eva l e n c e  o f  2 5 %  t o  3 0 %  i n  p a t i e n ts  w i t h  p r i m a ry  o r
metastatic breast cancer [5] and reported poor prognosis
[6-8].
Although lacking intrinsic ligand-binding capability,
HER2 acts as the preferred partner for the formation of
mitogenically active heterodimers with the cognate EGFR
family members epidermal growth factor 1 (HER1 or
EGFR), EGFR receptor 3 (HER3), and receptor 4 (HER4)
[4,9,10], HER2-HER3 being the prevalent and most
potent of these complexes [1,8,11]. HER2-containing het-
erodimers undergo slow endocytosis and more-rapid
recycling back to the cell surface [12-14]. These features
translate to potent mitogenic signal cascades involving
multiple signalling pathways [15].
HER2 is therefore a relevant target for HER2-overex-
pressing breast cancer therapy. Current targeted treat-
ments are based on the use of trastuzumab, a humanized
anti-HER2 monoclonal antibody [16-22] or antibodies
against other EGFR family members [23,24] or inhibitors
of selective tyrosine kinase receptor phosphorylation
sites [25-28].
An additional, still scarcely explored anti-HER2 treat-
ment may selectively target molecular mechanisms con-
trolling HER2 overexpression on the plasma membrane,
its lysosomal pathway-dependent degradation [29], and
recycling back to membrane domains [30]. By inhibiting
signal-transduction cascades triggered by HER2 het-
erodimer formation and affecting the downstream events
responsible for altered cell proliferation, survival, and
gene overexpression [31], this approach might comple-
ment or alternate with the present therapy protocols,
especially in cases of severe side effects (for example, car-
diotoxicity) or onset of specific resistance to currently
used agents [28,32,33].
In previous studies on aberrant phosphatidylcholine
(PC) metabolism in cancer cells [34-38], we reported that
inactivation of a 66-kDa PC-specific phospholipase C
(PC-PLC) enzyme, recruited to the plasma membrane of
mitogen-stimulated [39], cytokine-activated [40] and
tumor cells [41], downmodulates the expression on mem-
brane of specific receptors or proteins relevant to cell
function.
The present work reports the first evidence on PC-PLC
accumulation and association with HER2 on the plasma
membrane of HER2-overexpressing breast cancer cells
and on the effects of PC-PLC inhibition on HER2 inter-
nalization, degradation, and recycling and on cell prolif-
eration after transient or continuous cell exposure to
anti-HER2 monoclonal Abs, including trastuzumab.
Materials and methods
Antibodies and reagents
Rabbit polyclonal antibodies (pAbs) raised against bacte-
rial (Bacillus cereus) PC-PLC and selectively cross-react-
ing with mammalian PC-PLC [42] was obtained and
characterized as reported [39,43,44].
Anti-HER2 monoclonal antibodies (mAbs) 300G9 and
W6/100 were developed by Dr. P.G. Natali at the Istituto
Tumori Regina Elena (Rome, Italy). Rabbit anti-EGFR,
anti-HER2, anti-HER3, and anti-Rab5B pAbs were pur-
chased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-β-actin mAb was from Sigma-Aldrich (St.
Louis, MO, USA). Trastuzumab (Herceptin) and pro-
tease-inhibitor cocktail were from Hoffman-La Roche
(Basel, Switzerland). Anti-Lamp-2 mAb was supplied by
BD Biosciences (San Jose, CA).
Alexa Fluor-488 and -594 F(ab)2 fragments of goat anti-
rabbit IgG (H+L), Alexa Fluor-488 and -594 F(ab)2 frag-
ments of goat anti-mouse IgG (H+L) were purchased
from Molecular Probes Inc. (Eugene, OR, USA), and goat
anti-human FITC-conjugated from Cappel Co. (USA)
were used as secondary Abs.
Goat anti-mouse and goat anti-rabbit IgG horseradish
peroxidase (HRP)-conjugated antibodies and streptavi-
din-HRP were supplied by BioRad Laboratories, Inc.
(Hercules, CA, USA).
Triton X-100, NHS-biotin, propidium iodide, tricyclo-
decan-9-yl-potassium xanthate (D609), 5-bromo-2'-
deoxyuridine (BrdU), 3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), and all other chem-
icals and biochemicals were from Sigma-Aldrich, unless
otherwise specified.
Cells
Nontumorigenic, immortal human mammary epithelial
cell lines (MCF-10A and MCF-12A) and HER2-overex-
pressing (SKBr3, MDA-MB-453, BT-4T4) or HER2-low
(MCF7, MDA-MB-231, MDA-MB-435) human mam-
mary carcinoma cell lines were from American Type Cul-
ture Collection (ATCC, Rockville, MD).
MCF-10A and MCF-12A cells were cultured in DMEM
F12 medium, supplemented with 5% horse serum, hydro-
cortisone (0.5 μg/ml), insulin (10 μg/mL), hEGF (20 ng/
mL), and gentamicin/amphotericin-B (Gibco Laborato-
ries, Grand Island, NY, USA). MCF7, MDA-MB-231 and
MDA-MB-435 cells were grown in DMEM (Gibco Labo-
ratories) supplemented with 1,000 g/L glucose and 10%
foetal bovine serum (FBS). MDA-MB-453 and SKBr3
cells were cultured in DMEM supplemented with 1,000 g/Paris et al. Breast Cancer Research 2010, 12:R27
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L glucose/10% FBS and 4500 g/L glucose/5% FBS (Gibco),
respectively. BT-474 cells were cultured in RPMI supple-
mented with 10% FCS. Cells were typically analyzed at
subconfluence, 72 hours after seeding.
Proliferation assay
Cell-proliferation/viability assays were performed on cells
exposed for 2 hours to MTT (5 μg/mL in PBS) at 37°C, in
5% CO2 [45,46]. Optical absorbance was measured (in six
replicates) at 595 nm with a Model 680 Microplate
Reader (BioRad Laboratories).
Western blot analyses
Preparation of total cell lysates, determination of protein
concentration and Western blot analyses were performed
as previously described [41]. Blots were incubated with
anti-HER2 (Santa Cruz Biotechnology) or anti-PC-PLC
pAbs. Densitometric analysis of protein bands was per-
formed as reported [41].
In vitro PC-PLC activity assay
PC-PLC activity was determined in whole-cell lysates by
using the Amplex Red PC-PLC-specific assay kit (Molec-
ular Probes Inc.), modified as described [47].
Separation of lipid rafts by sucrose gradient
Cell lysis, gradient fractionation (5% to 30% sucrose), and
protein separation were carried out as previously
described [40,41,48]. The distribution of HER2 and PC-
PLC in the gradient fractions was assessed by separation
in 7% SDS-PAGE followed by Western blotting.
Cell surface biotinylation
SKBr3 cells were biotinylated on plasma membrane by
adding 1.5 mg of NHS-biotin that links to hystidine and
lysine proteins residues, and then lysed in ice-cold lysis
buffer and immunoprecipitated with anti-PC-PLC poly-
clonal Abs. Detection of biotinylated proteins was per-
formed by using streptavidin-HRP.
Immunoprecipitation
Samples for immunoprecipitation were prepared as pre-
viously described [40]. In brief, total cell lysates (1 mg in 1
mL) were incubated with 10% protein G Sepharose
(Amersham Biosciences, Uppsala, Sweden) and with anti-
HER2 (Santa Cruz Biotechnology) or anti-PC-PLC spe-
cific Abs overnight at 4°C. After extensive washing, beads
were removed by centrifugation at 14,000 rpm and then
SDS sample buffer 4×, containing 2-mercaptoethanol
(ICN Biomedicals Inc., Irvine, CA, USA) was added to
elute proteins by heating the sample at 100°C for 5 min-
utes. Immunoprecipitates were resolved by 7% SDS-
PAGE under reducing conditions and blotted with related
Abs.
Confocal Laser Scanning Microscopy (CLSM) and flow 
cytometry analyses
CLSM observations were performed on either unfixed or
fixed and permeabilized cells, as already reported [41].
Flow-cytometry analyses were performed as previously
described [39].
Statistical analysis
Data were analyzed by using GraphPad software, version
3.03. Statistical significance of differences was deter-
mined with one-way ANOVA or with Student's t test, as
specified. Differences were considered significant at P <
0.05.
Results
Accumulation of PC-PLC on the outer-membrane surface of 
breast HER2-overexpressing epithelial tumor cells
CLSM and flow-cytometry analyses on unfixed cells
showed barely detectable PC-PLC levels on the plasma
membrane of the nontumoral immortalized breast epi-
thelial cell lines MCF-10A (Figure 1a and 1b) and MCF-
12A (data not shown). A massive, spotlike accumulation
of PC-PLC was instead detected on the outer surface of
the HER2-overexpressing breast carcinoma cell lines
SKBr3 and MDA-MB-453. Similar fluorescence patterns
were detected in BT-474 cells (Supplemental figure S1 in
Additional file 1). In HER2-low cancer cells, PC-PLC-
positive granules were smaller and less abundant (Figure
1a and 1b).
The percentage of PC-PLC-positive HER2-overex-
pressing cells (Figure 1c) was significantly higher (78% ±
13% in SKBr3; 61% ± 6% in MDA-MB-453; P < 0.001)
than that of HER2-low tumor cells (MCF-7, 26% ± 7%;
MDA-MB-231, 21% ± 15%; MDA-MB-435, 8% ± 3%) and
nontumoral MCF-10A cells (<5% ± 2%).
These results show that PC-PLC selectively accumu-
lates on the plasma membrane of HER2-overexpressing
breast cancer cells.
Colocalization and association of PC-PLC with HER2 on the 
plasma membrane of SKBr3 cells
CLSM analyses of unfixed SKBr3 cells showed extensive
colocalization of PC-PLC and HER2 on the outer plasma
membrane surface (Figure 2a, top and middle panels).
Similar colocalization of the two proteins was observed
on the plasma membrane of BT-474 cells (Supplemental
figure S1 in Additional file 1).
Analyses of fixed SKBr3 cells showed that PC-PLC was
also present in inner cell compartments including the
nucleus (Figure 2a, bottom panel), whereas the HER2
receptor was, as expected, essentially confined to the
plasma membrane.Paris et al. Breast Cancer Research 2010, 12:R27
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Exposure of PC-PLC on the outer cell surface was con-
firmed by biotinylation on the membrane, followed by
lysis and immunoprecipitation with anti-PC-PLC pAbs
(Figure 2b, lane IP α-PC-PLC). Specific recognition by
both streptavidin-HRP and anti-PC-PLC antibody of a
biotinylated protein with a molecular mass of 66 kDa [39-
41], identified the presence of a substantial fraction of
PC-PLC on the outer membrane surface. Few additional
bands detected at both lower and higher Mr values were
tentatively attributed to PC-PLC fragments and proteins
associated with PC-PLC at the plasma membrane level.
Western blot analyses on sucrose-gradient fractions of
total cell lysates showed that both HER2 (185 kDa) and
PC-PLC were mostly present in detergent-insoluble
membrane raft domains (Figure 2c, lanes 4 through 6),
although low PC-PLC contents were also detected in the
detergent-soluble fractions (Figure 2c, lanes 8 through
12).
Figure 1 PC-PLC expression on plasma membrane of breast cancer cells. (a) CLSM analyses of six unfixed cell lines stained for PC-PLC detection 
(pseudo-color grey). Upper panels show examples of a three-dimensional reconstruction of a single cell (scale bars, 5 μm); the lower panels show sin-
gle central sections of a group of cells (scale bars, 20 μm). Nuclei were stained with DAPI (blue). (b, c) FACS analyses of unfixed cells: representative 
cytofluorimetric histograms of PC-PLC relative fluorescence intensity of the indicated cell lines (b) and percentage (mean ± SD) of PC-PLC positive 
cells (c). Statistical significance of differences between HER2-overexpressing (SKBr3 and MDA-MB-453) and HER2-non-overexpressing (MDA-MB-231, 
MCF-7, MDA-MB-435) carcinoma cell lines was P < 0.001. Five independent experiments were performed on each cell line.Paris et al. Breast Cancer Research 2010, 12:R27
http://breast-cancer-research.com/content/12/3/R27
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Figure 2 Colocalization of PC-PLC and HER2 on plasma membrane of SKBr3 cells. (a) CLSM detection of PC-PLC and HER2 in either unfixed (top 
and middle panels) or fixed and permeabilized SKBr3 cells (bottom panel) by using rabbit polyclonal α-PC-PLC (green) and α-HER2 W6/100 mAb (red). 
Colocalization areas are represented in yellow. The middle panel shows the tridimensional reconstruction of PC-PLC and HER2 expression on the plas-
ma membrane. Scale bars, 8 μm. At least five independent series of experiments were performed for each condition. (b) PC-PLC immunoblotting anal-
yses of immunoprecipitated biotinylated proteins isolated from SKBr3 cells, detected by streptavidin-HRP (left, IB:STREP HRP) or by α-PC-PLC (right, 
IB:α-PC-PLC). TL, total lysate; bTL, biotinylated total lysate; CTR IgG, control for α-PC-PLC IgG; IP α-PC-PLC, α-PC-PLC immunoprecipitates. *IgG heavy 
chains. (c) Sucrose gradient fractions isolated from SKBr3 cell lysates and analyzed by Western blotting for HER2 (185 kDa) and PC-PLC (66 kDa) detec-
tion. T, total cell lysate. (d, e) Western blot analyses of α-HER2 and α-PC-PLC (d) and α-EGFR and α-PC-PLC (e) immunoprecipitates (IP), blotted with 
the mutual Abs (α-PC-PLC, α-HER2, and α-EGFR, respectively), compared with the respective controls (CTR IgG α-PC-PLC, CTR IgG α-HER2, CTR IgG α-
EGFR). Panels b, c, d, show representative results of three independent experiments. The immunoprecipitation in panel e was repeated twice.Paris et al. Breast Cancer Research 2010, 12:R27
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Finally, combined co-immunoprecipation and Western
blotting experiments showed that HER2 immunoprecipi-
tates were associated with PC-PLC molecules (Figure 2d,
lane IP α-HER2) and, conversely, a substantial amount of
HER2 was present in PC-PLC immunoprecipitates (Fig-
ure 2d, lane IP α-PC-PLC).
Regarding other receptor-family members, EGFR (170
kDa, Figure 2e) but not HER3 (180 kDa, not shown) was
also found to co-immunoprecipitate with PC-PLC.
These results provide evidence of the existence of a
physical association between PC-PLC and HER2 (and
EGFR) in HER2-overexpressing breast cancer cells.
PC-PLC inhibition induces downmodulation of HER2 
expression on the SKBr3 plasma membrane
Possible effects of PC-PLC inactivation on HER2 expres-
sion on plasma membrane were investigated on SKBr3
cells cultured in the presence of the PC-PLC inhibitor
D609. A 3.5-fold decrease in PC-PLC activity was
achieved within 1 hour and was maintained up to 72
hours of cell incubation with D609 (Figure 3a, black col-
umns). CLSM analyses showed a progressive downmodu-
lation of both HER2 (red) and PC-PLC (green) on the
membrane surface of cells exposed to D609, an effect
already evident at 6 hours, and almost complete at 24
hours (Figure 3b). At this time, a small residual amount of
PC-PLC was still detected on the cell surface.
Inhibition of PC-PLC induces HER2 internalization and 
block of the receptor recycling
To investigate the effects of PC-PLC inhibition on HER2
expression on cell membrane, internalization, and recy-
cling, CLSM analyses were performed on fixed and per-
meabilized SKBr3 cells after incubation in the presence of
D609. A substantial amount of HER2 was internalized as
small cytoplasmic vesicles within 1 hour of incubation
(Figure 4), and at 6 hours, the receptor was mainly local-
ized in large clusters close to the nucleus. Finally, at 24
hours, HER2 practically disappeared from the plasma
membrane. The cytoplasmic PC-PLC distribution also
underwent marked changes from a fine and diffuse distri-
bution at t = 0 to large cytoplasmic granules at 6 hours,
with progressive appearance of positive clumps inside the
nucleus at 6 to 24 hours (Figure 4).
Similar HER2 downmodulation on the membrane was
observed in BT-474 cells after exposure to D609 (Supple-
mental figure S2b in Additional file 2, column D609).
Notably, these cells form clusters in which anti-HER2 Abs
penetrate, allowing effective HER2 staining. However,
small agents such as DAPI preferentially penetrate into
peripheral cells (Supplemental figure S2a in Additional
file 2). It is probably for this reason that the major effect
of D609 was observed mostly on cells located at the
periphery of BT-474 clusters.
The intracellular redistribution and trafficking of HER2
after D609-induced internalization was further investi-
gated by CLSM on fixed and permeabilized SKBr3 cells
stained with either the early endosomal marker Rab5B or
the lysosomal-associated membrane protein-2 (Lamp-2),
at different times of cell exposure to the PC-PLC inhibi-
tor.
No evident colocalization of the receptor with either
Rab5B- or Lamp-2-positive vesicles (Figure 5a, panels a
and e, green) was observed at t = 0. In cells incubated
with D609, most of internalized HER2 colocalized with
early endosomes at 3 hours (panel b), only a small portion
being associated with lysosomes (panel f). Both endo-
somal and lysosomal vesicles contained rather large
HER2-positive clusters at 6 hours (panels c and g),
whereas the receptor was mostly internalized into lyso-
somes at 24 hours (panels d and h).
Immunoblotting analyses showed a 70% decrease in the
cellular HER2 content at 24 hours of cell incubation with
D609 (Figure 5b), consistent with the enhanced receptor
degradation in endosomes and lysosomes. No significant
changes were detected in the overall cellular PC-PLC
content.
These results showed that PC-PLC inhibition resulted
in enhanced endosomal and lysosomal HER2 internaliza-
tion, with downmodulation of this receptor on the
plasma membrane.
Effects of D609 on Ab-mediated HER2 internalization
HER2 engagement by specific Abs is known to induce
receptor internalization from plasma membrane to inner
cell compartments [29,49,50]. Experiments were there-
fore designed to explore whether PC-PLC inhibition
could also interfere with the rates of Ab-mediated HER2
endocytosis, degradation, and reexpression on cell mem-
brane. To this end, after short-time engagement with the
anti-HER2 mAb 300G9 (30 minutes, on ice) followed by
Alexa Fluor-594 Gα M Ab (red fluorescence), SKBr3 cells
were incubated at 37°C in Ab-free medium in either the
absence or the presence of D609 (Figure 6a). At selected
time intervals, viable cells were stained again, at 4°C, on
plasma membrane with a different anti-HER2 mAb (W6/
100), followed by Alexa Fluor-488 as secondary Ab (green
fluorescence), to monitor the time course of HER2 reex-
pression on the cell membrane (Figure 6a, green). Inter-
nalization of the "old" Ab-engaged receptor was therefore
monitored in red, whereas reexpression on the mem-
brane of "new" receptor molecules was monitored in
green. Although the kinetics of HER2 internalization was
likely altered by the presence of the secondary Ab, this
experimental setting enabled us to investigate D609-
induced changes in the repopulation of the plasma mem-
brane with newly synthesized HER2 molecules.Paris et al. Breast Cancer Research 2010, 12:R27
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Experiments on control cells (not exposed to D609)
showed that a substantial amount of "old" HER2 receptor
molecules was endocytosed within 1 hour from Ab
engagement (Figure 6a, panel b, red), was mostly detected
in cytoplasmic areas at 3 to 6 hours (panels c and d, red),
and practically disappeared from the cell at 24 hours,
likely because of lysosomal degradation (panel e, red).
Reexpression on the membrane surface of "new" HER2
molecules was detected as early as 1 hour after Ab
engagement (Figure 6a, panel b, green) and already
returned to control values at 3 hours (panel c, green).
In the presence of D609, the rate of endocytosis of Ab-
engaged HER2 molecules was quite similar to that of cells
incubated in the absence of D609 but, interestingly, the
cross-linked receptor underwent a much slower degrada-
tion; a portion of the originally engaged "old" HER2 mole-
cules was still detectable in cytoplasmic areas at 48 hours
(Figure 6a, panel n, red).
Furthermore, cell incubation with D609 induced a
striking retardation in the reexpression of "new" HER2
molecules on the membrane surface (Figure 6a, panel l,
green), because newly expressed receptor molecules were
still below detection level at 24 to 48 hours (panels m and
n, green), suggesting a long-lasting block of receptor
recruitment to the cell surface. The effect of D609 on
reexpression on the plasma membrane vanished at 72
hours of cell incubation with this inhibitor, when the "old"
originally Ab-engaged receptor had been totally degraded
(panel o, green and red staining, respectively).
Figure 3 D609-induced PC-PLC inhibition and HER2 downmodulation in SKBr3 cells. (a) Amplex Red® assay SKBr3 cells after exposure to the PC-
PLC inhibitor D609. Relative PC-PLC activity was measured in the presence of D609 (50 μg/mL, black columns) and compared with that of untreated 
control cells (t = 0 taken as 1.0 or t = 72 hours, white columns). Histograms represent the mean ± SD (n = 4). (b) CLSM analyses of unfixed SKBr3 cells 
cultured in complete medium (t = 0) and in presence of D609 for the indicated time periods. After washing, cells were stained with α-PC-PLC (green) 
and α-HER2 (red). Nuclei were stained with DAPI (blue). Colocalization areas are represented in yellow. Scale bars, 5 μm. These experiments were in-
dependently repeated 3 times.Paris et al. Breast Cancer Research 2010, 12:R27
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Western blot analyses performed on total lysates of
SKBr3 cells transiently engaged with the anti-HER2 Abs
(Figure 6b) showed that the overall cellular HER2 content
remained constant in the absence of D609, whereas it
decreased to 52% ± 2% by 6 hours of cell incubation with
D609, remained low at 24 hours, and gradually reverted
to basal levels at 48 to 72 hours.
Figure 4 Effect of PC-PLC inhibition on HER2 internalization in 
SKBr3 cells. CLSM analyses of SKBr3 cells cultured in complete medi-
um either in the absence (t = 0) or presence of D609 (50 μg/mL) for the 
indicated incubation times. After washing, cells were fixed and stained 
with α-PC-PLC (green) and α-HER2 Abs (red). Nuclei were stained with 
DAPI (blue). Colocalization areas were represented in yellow (merge 
between green and red) or cyan (merge between green and DAPI). 
Scale bars, 8 μm. Panels show representative examples of five indepen-
dent series of experiments.
Figure 5 Effects of D609 on trafficking and degradation of HER2 
receptor molecules in SKBr3 cells. (a) CLSM analyses of SKBr3 cells, 
incubated for the indicated time intervals with the PC-PLC inhibitor 
D609 (50 μg/mL) and then fixed and stained with the α-HER2 mAb W6/
100 (red) and α-Rab5B Ab (green, panels a through d) or α-Lamp 2 Ab 
(green, panels e through h). Nuclei were stained with DAPI (blue). Scale 
bars, 8 μm. (b) Western blot analyses of total lysates of SKBr3 cells ei-
ther untreated or incubated with D609 for 6 and 24 hours. The blots 
were incubated with α-HER2 or α-PC-PLC Abs. Actin was used as quan-
titative loading control. Experiments shown in panels a and b were in-
dependently repeated 3 and 4 times, respectively.Paris et al. Breast Cancer Research 2010, 12:R27
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When HER2 was transiently engaged with the human-
ized antibody trastuzumab, the time course of receptor
internalization (Supplemental figure S3 in Additional file
3, panels b through f, red) was similar to that observed in
cells engaged with the 300G9 mAb (Figure 6, left panels)
with only minor differences.
Overall, these results show that similar rates of HER2
internalization occurred under the adopted conditions in
SKBr3 cells transiently cross-linked with a specific anti-
HER2 Ab, irrespective of the presence of D609 in the
medium. However, when incubation occurred in the
presence of D609, the degradation of the originally Ab-
engaged receptor was much slower, and reexpression on
the membrane of new receptor molecules was strongly
retarded (for at least 48 hours).
When SKBr3 cells were continuously exposed to trastu-
zumab, CLSM analyses on cells fixed at the end of the
incubation period failed to show any significant change in
total HER2 expression on the membrane (Figure 7a, left
panels), in agreement with a previous report [51]. How-
ever, in the presence of D609, a clearcut loss of HER2 was
noted at the membrane level at 5 hours, which lasted for
at least 48 hours (Figure 7, right panels). Immunoblotting
experiments (Figure 7b) showed very substantial losses of
overall HER2 content in subconfluent cells exposed to
D609 (mean residual values versus controls of 67% ± 11%
at 24 hours; 36% ± 8% at 48 hours; and 51% ± 18% at 72
hours) or to a combination of D609 and 10 μg/mL trastu-
zumab (54% ± 30% at 24 hours; 16% ± 1% at 48 hours, and
25% ± 6% at 72 hours), compared with trastuzumab alone
(100% ± 4% at 24 hours; 81% ± 3% at 48 hours, and 79% ±
18% at 72 hours). Decreases in HER2 contents were also
detected in MDA-MB-453 cells exposed to D609 (50% to
70% of control values at 24 to 72 hours) or to D609 com-
bined with 50 μg/mL trastuzumab (30% to 60%) com-
pared with trastuzumab alone (80% to 60%). These results
showed substantial D609-induced HER2 decreases in
these cells basically resistant to trastuzumab [52]. D609,
either alone or in combination with 10 μg/mL trastu-
zumab, also induced a decrease in the HER2 content of
trastuzumab-sensitive BT-474 cells at 72 hours (40% ±
10%), an effect comparable to that of trastuzumab alone.
PC-PLC inhibition reduces membrane expression of EGFR 
and HER3 and formation of their heterodimers with HER2 in 
SKBr3 cells
To investigate whether PC-PLC inhibition could also
induce alterations on membrane expression of other
EGFR family members and formation of their heterodim-
ers with HER2, combined CLSM, immunoblotting, and
immunoprecipitation experiments were performed on
SKBr3 cells incubated either in the presence or the
absence of D609.
Figure 6 D609-induced retardation of reexpression of HER2 on 
the plasma membrane of SKBr3 cells after short-term receptor 
engagement with an anti-HER2 antibody. (a) CLSM examinations 
on unfixed cells transiently engaged (30 minutes at 4°C) with α-HER2 
mAb 300G9, followed by goat α-mouse Alexa Fluor-594 (panel a, red), 
then cultured at 37°C for the indicated time periods in complete Ab-
free medium, either in the absence (b through g) or presence of D609, 
50 μg/mL (h through o). At the end of each time interval, cells were 
stained again on the plasma membrane with the α-HER2 W6/100 mAb, 
followed by goat α-mouse Alexa Fluor-488 (green). Nuclei were 
stained with DAPI (blue). Scale bars, 8 μm. These analyses were inde-
pendently performed 3 times. (b) Western blot analyses of SKBr3 cells 
first engaged with α-HER2 300G9 mAb, followed by goat α-mouse an-
tibody, and then cultured at 37°C either in the absence or presence of 
D609 for the indicated time periods. The blots were incubated with α-
HER2 or with anti-β actin Abs. These experiments were repeated on 
seven sets of independent cell preparations.Paris et al. Breast Cancer Research 2010, 12:R27
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CLSM analyses of untreated and fixed SKBr3 cells
showed that, as expected, both HER3 and EGFR were
expressed mainly on the plasma membrane, although the
two receptors were differently distributed among inner
cell compartments (Figure 8a). A substantial amount of
HER3 (but not EGFR) was also detected in nuclear areas.
Cell exposure to D609 for 24 hours induced downmod-
ulation from the plasma membrane of both HER3 and
EGFR, although the two receptors followed different rates
of internalization (Figure 8a). In particular, HER3 almost
disappeared from the plasma membrane within 1 hour of
cell exposure to D609, and only a small residual amount,
confined mainly to the nucleus, was detected at 24 hours.
At the latter time point, immunoblotting experiments on
total cell lysates confirmed a strong decrease in the over-
all HER3 content (Figure 8b). Under these conditions,
immunoprecipitation with anti-HER3 followed by detec-
tion with anti-HER2 Abs showed that HER2-HER3 het-
erodimers, clearly detected in control cells, practically
disappeared in D609-treated cells (Figure 8b). This result
was further confirmed by immunoprecipitation with
anti-HER2 followed by detection with anti-HER3 Abs
(data not shown).
CLSM analyses on D609-treated cells showed that the
rate of EGFR endocytosis was very similar to that of
HER2 internalization (compare lower panels of Figure 8a
with Figure 4). Under these conditions, a clear decrease in
the overall EGFR content was detected with Western
blotting of total lysates of cells collected after 24 hours of
exposure to D609. Co-immunoprecipitation experiments
showed a simultaneous decrease in HER2-EGFR het-
erodimers (Figure 8b).
In conclusion, these results showed that 24 hours of cell
exposure to the PC-PLC inhibitor induced a substantial
decrease in both HER2-HER3 and HER2-EGFR heterodi-
mers, a result that could derive not only from reduced
HER2 expression (Figure 5), but also from the decreased
contents of the respective partners.
Effects of D609 on cell proliferation of HER2-
overexpressing breast cancer cells
MTT assays showed that trastuzumab failed to exert sig-
nificant antiproliferative effects (P > 0.05) on SKBr3 cells
continuously exposed for 24 to 72 hours to this agent at
doses of either 10 μg/mL (Figure 9a) or 50 μg/mL (data
not shown).
A strong reduction in the percentage of viable/prolifer-
ative cells was instead detected in SKBr3 cells exposed to
D609 for 24 to 72 hours (down to 20% to 30% of the origi-
nal levels in untreated control cells; P < 0.005). Combina-
tion of D609 with trastuzumab (10 μg/mL) had similar
antiproliferative effects to those induced by D609 alone
(Figure 9a). Different antiproliferative patterns were
detected in the trastuzumab-sensitive BT-474 cells, in
which this mAb reduced to 70% to 75% the percentage of
viable/proliferative cells at 48 to 72 hours (P < 0.02). Very
similar antiproliferative effects were induced by D609 or
a combination of the two agents (Figure 9b), although it
cannot be excluded that differential penetration of D609
in BT-474 clusters led to less-efficient PC-PLC inhibition.
Intermediate antiproliferative effects were exerted at 48
to 72 hours by D609 or D609 plus trastuzumab (50 μg/
mL) in MDA-MB-453 cells (Figure 9c).
Figure 7 Effect of D609 on HER2 expression in SKBr3 cells contin-
uously exposed to trastuzumab. (a) CLSM analyses of cells fixed after 
exposure for the indicated time intervals to trastuzumab, in the pres-
ence or absence of D609. Nuclei were stained with DAPI (blue). Scale 
bars, 20 μm. (b) Decrease in the overall HER2 content, detected by 
Western blotting, in total lysates of cells after incubation for different 
time intervals with D609 (50 μg/mL), trastuzumab (HERC, 10 μg/mL), or 
their combination (COMB). CTR, untreated control cells. Both CLSM 
and immunoblotting analyses were repeated 3 times.Paris et al. Breast Cancer Research 2010, 12:R27
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Figure 8 Effects of PC-PLC inhibition on EGFR and HER3 internalization, overall receptors' contents and heterodimer formation with HER2. 
(a) CLSM analyses of fixed SKBr3 cells after exposure to D609 for different time intervals and stained with either α-HER3 (upper panels) or α-EGFR an-
tibodies (lower panels). Nuclei were stained with DAPI (blue). Scale bars, 20 μm. (b) Immunoblotting (IB) and immunoprecipitation (IP) experiments 
on SKBr3 cells, incubated with D609 for 24 hours, to detect overall HER3 and EGFR contents (left panels) and their levels of heterodimerization with 
HER2 (right). Central panels show the efficiency of the α-HER3 and α-EGFR antibodies in immunoprecipitating the respective target receptors. ET CTR, 
total extract of control cells; ET D609, total extract of D609-treated cells; CTR IgG, control IgG of α-HER3 or α-EGFR antibodies; IP CTR, immunoprecip-
itation from control cells; IP D609, immunoprecipitation from D609-treated cells. Representative examples of two independent experiments are 
shown.Paris et al. Breast Cancer Research 2010, 12:R27
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In conclusion, evident antiproliferative effects were
associated with PC-PLC inhibition, especially in trastu-
zumab-resistant cells.
Discussion
This study provided the first evidence that (a) PC-PLC, a
phospholipase involved in mitogenic response, cell sig-
nalling, apoptosis, and survival [53-56], colocalizes with
HER2 in membrane-raft domains of HER2-overexpress-
ing breast cancer cells; and (b) PC-PLC inhibition
induces in these cells enhanced HER2 internalization, fol-
lowed by long-lasting HER2 accumulation in endosomal/
lysosomal compartments and retarded HER2 reexpres-
sion on membrane. Moreover, PC-PLC was found to be
physically associated with both HER2 and EGFR, but not
with HER3 receptors, and PC-PLC inactivation resulted
in striking decreases in the overall cellular contents of
EGFR, HER2, HER3, and their heterodimers. Cell expo-
sure to a PC-PLC inhibitor exerted an antiproliferative
effect, especially on trastuzumab-resistant cells.
Molecular interaction between HER2 and PC-PLC on the 
plasma membrane of SKBr3 cells
A previous study in our laboratory showed that inactiva-
tion of PC-PLC in human NK cells caused CD16 receptor
downmodulation on membranes and reduced NK cyto-
toxicity [40]. Involvement of PC-PLC in the mitogenic
response and growth-factor-dependent colocalization
with β1-integrin was reported in ovarian cancer cells [41].
No information was available on subcellular localization
and the role of PC-PLC in breast cancer cells, although
preliminary evidence on activation of this enzyme has
been reported [57]. The present study shows that PC-
PLC accumulates on the cell surface of HER2-overex-
pressing cells, in which this phospholipase colocalizes
with HER2 in membrane raft domains. Significantly
lower PC-PLC levels were instead detected on the mem-
brane of HER2-low breast cancer cells characterized by
different malignancy phenotypes.
Colocalization of PC-PLC with HER2 on the plasma
membrane of SKBr3 cells was due to physical association,
because the two proteins were co-immunoprecipitated by
the respective antibodies. Although identification of the
chemical domains responsible for this molecular interac-
tion needs elucidation of the structure of this still-unse-
quenced mammalian phospholipase, the association of
HER2 with an active PC-PLC isoform is apparently an
important requirement for maintaining this receptor
anchored to functional membrane domains. Inhibition of
PC-PLC activity was followed by fast downmodulation of
the oncoprotein from the cell membrane, associated with
endocytosis and targeting to degradative intracellular
compartments.
The molecular mechanisms responsible for enhanced
HER2 endocytosis and altered rate of degradation in
HER2-overexpressing breast cancer cells exposed to the
PC-PLC inhibitor remain to be elucidated. Previous stud-
ies by Kappler et al. [58] and Raja et al. [29] suggested a
role for the endocytic pathway in HER2 downmodula-
tion. In particular, a potent downregulation of the cell-
surface HER2, associated with enhanced ubiquitinylation
and lysosomal pathway-dependent degradation of this
receptor and cell growth arrest was recently reported in
HER2-overexpressing breast cancer cells treated with a
combination of HSP90 inhibitor 17-AGG and trastu-
zumab [29]. The authors suggested that these agents may
affect the interaction of HER2 with ubiquitin ligases, with
subsequent changes in HER2 ubiquitinylation, by altering
Figure 9 Antiproliferative effect of PC-PLC inhibition on HER2-
overexpressing cells. MTT assays on (a) SKBr3 and (b) BT-474 cells 
both exposed to trastuzumab (HERC, 10 μg/mL), or (c) MDA-MB-453 
exposed to trastuzumab (50 μg/mL), after incubation for the indicated 
times with D609, trastuzumab (HERC), or their combination (COMB). 
The percentage of cell proliferation was calculated by defining the ab-
sorption of untreated cells as 100%. Histograms represent the mean 
percentage of independent series of assays (± SD for SKBr3 and BT-474 
(n = 3); or ± maximum deviation for MDA-MB-453 (n = 2)). Significance 
of differences: **P ≤ 0.02; ***P < 0.005.
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the arrangement of the HER2-associated HSP90 chaper-
one complex. These findings support the interest of
exploring in our cell systems how deactivation of HER2-
associated PC-PLC affects the differential recruitment of
specific ubiquitin ligases to HER2 and cognate members
of the EGFR family. We might hypothesize that deactiva-
tion of PC-PLC isoform(s) associated with HER2 likely
modifies the efficiency of ubiquitinylation and lysosomal
degradation through changes in steric hindrance effects
or structural changes of HER2 complexes or both.
Our results point to the attractive possibility of control-
ling, by a simple switch of the activity status of PC-PLC,
t h e  l e v e l s  o f  H E R 2  e x p r e s s i o n  o n  t h e  m e m b r a n e  a n d
therefore reducing the formation of HER2 heterodimers
with cognate members of the EGFR family, with expected
effects on the control of tumorigenicity of HER2-overex-
pressing cells. By enhancing HER2 endocytosis and lyso-
somal degradation and retarding HER2 recycling to the
membrane, PC-PLC inhibition resulted in HER2-EGFR
and HER2-HER3 depletion. Similar effects on HER2 het-
erodimers have so far been achieved by more-complex
laboratory procedures such as induction of intracellular
expression of single-chain HER2-specific antibodies in
cancer cells [59,60]. The D609-induced reduction in the
levels of HER2-HER3 and HER2-EGFR heterodimers
may originate from differential mechanisms, because co-
immunoprecipitation experiments showed the physical
association of PC-PLC with either HER2 or EGFR but not
with HER3. Possibly linked to this differential behavior is
the much faster downmodulation of HER3 from the cell
membrane after PC-PLC inactivation. This result sug-
gests the hypothesis that inhibition of PC-PLC activity
may facilitate dissociation of HER2-HER3 heterodimers,
with possible effects on diversification of HER2-driven
intracellular cascades of downhill phosphorylation reac-
tions [11]. Analyses s hould also be e xt ended t o HER4,
temporarily excluded from this phase of the study.
Role of PC-PLC activity in controlling HER2 recycling
Alterations of cell recycling of HER2 in breast cancer cells
may also have profound effects on cell-signalling deregu-
lation in HER2-overexpressing cells [12-14]. The
reported downmodulation of HER2 from the plasma
membrane of HER2-overexpressing cells exposed to the
PC-PLC inhibitor suggests that PC-PLC has a role in con-
trolling the effects of the overall HER2-amplification
machinery. Our experiments on cells engaged by anti-
HER2 Abs showed that fast receptor internalization and
degradation was followed by rapid reexpression of new
HER2 molecules on the membrane surface, consistent
with the capability of these cancer cells to restore and
maintain high expression levels of the amplified HER2
receptor. In contrast, addition of D609 to cells incubated
in Ab-free medium after transient receptor-mAb cross-
linking, not only induced further receptor endocytosis,
and prolonged receptor degradation within lysosomal
structures, but also slowed reexpression of newly synthe-
sized HER2 molecules on the membrane. When cells
were continuously exposed in vitro to trastuzumab (a
condition similar to that of tumor cells after intravenous
infusion of this agent to the patient), no substantial
change in the expression of HER2 on the plasma mem-
brane was observed. This effect was in good agreement
with a previous report by Longva et al. [51] showing a
substantial lack of endocytotic downregulation of HER2
in SKBr3 cells exposed to trastuzumab. When, however,
cells were exposed to both trastuzumab and D609, a clear
decrease in HER2 expression on the membrane lasted for
at least 48 hours. Furthermore, a most striking effect
induced, under these conditions, by the PC-PLC inhibitor
was a strong and prolonged decrease in the overall cellu-
lar HER2 content, which lasted up to 72 hours.
Reduced cell proliferation of SKBr3 cells exposed to the PC-
PLC inhibitor
Among the multiple antitumor activities exerted by tras-
tuzumab on HER2-overexpressing breast cancer cells,
inhibition of cell proliferation is reported to occur pri-
marily by modulation of the cyclin-dependent kinase
inhibitor p27Kp1, via a complex network of signalling
pathways, resulting in G1 arrest and growth inhibition
[61].
This work shows a substantial lack of synergism
between the antiproliferative effects exerted by trastu-
zumab and D609, these processes likely being regulated
by different, independent molecular mechanisms. More-
over, the antiproliferative effect of D609 can hardly be
regarded as specific for HER2-overexpressing cells,
because previous studies in our laboratory showed that
cell exposure to this xanthate is able to induce cell-cycle
arrest in G0/G1 in different types of cells, such as HER2-
non-overexpressing ovary cancer cells and mitogen-stim-
ulated fibroblasts [39,40]. Further studies are needed to
investigate whether and to what extent the antiprolifera-
tive effect of D609, similar to that of another PC-PLC
inhibitor, SC-ααδ9 (4-(benzyl-(2- [(2,5-diphenyoxazole-
4-carbonyl)amino]ethyl)carbamoyl)-2-decanolaminobu-
tyric acid), is linked to the phosphorylation or inhibition
or both of selective cyclin-dependent kinase activities
[62].
Although a number of PC-PLC inhibitors have been
identified or designed [63-65], D609 is widely accepted as
selective competitive inhibitor of PC-specific phospholi-
pase both in reaction mixtures and in cells [66]. This
compound, first introduced as antiviral and antitumoral
agent  in vitro and  in vivo [66-70], has been shown to
enhance the action of other drugs in the regression ofParis et al. Breast Cancer Research 2010, 12:R27
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various human tumor transplants in athymic mice [68],
without side effects.
Our reported evidence on multiple effects induced by
D609 on HER2 downmodulation from the plasma mem-
brane suggests the interest of further evaluating in appro-
priate model systems the added value of including a PC-
PLC inhibitor as an adjunct to the current therapies tar-
geted against HER2-overexpressing breast cancer cells.
Conclusions
A C-type phospholipase specific for the major phospho-
lipid of eukaryotic cells associates with HER2 and EGFR
receptors in HER2-overexpressing breast cancer cells.
Inhibition of this enzyme induces downregulation of
HER2 expression on the plasma membrane of these cells,
promotes HER2 endocytosis and lysosomal degradation,
induces retardation in HER2 recycling, and is associated
with reduction of overall HER2, HER2-HER3, and HER2-
EGFR contents.
The use of a PC-PLC inhibitor as a modulator of HER2
overexpression and internalization in breast cancer cells
may allow a better elucidation of the complex, still
incompletely understood molecular mechanisms under-
lying cell tumorigenicity associated with HER2/neu gene
amplification.
The results of this study point to PC-PLC inhibition as
a possible means to counteract the tumorigenic effects of
HER2 amplification and complement the effectiveness of
current HER2-targeting therapies aimed at increasing
disease-free and overall survival of patients affected by
HER2-overexpressing breast cancer.
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